Adhesion Proteins in the Biology of Breast Cancer: Contribution of CD44

Herrera-Gayol, Andrea; Jothy, Serge

doi:10.1006/exmp.1999.2251

Cited by 93 publications

(69 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bànkfalvi et al indicated that myoepithelial cells expressed CD44 in normal breast epithelium, and that this is implicated in the early stage of breast carcinogenesis (21). Herrera-Gayol et al observed that CD44 expression was involved in two of the three steps of the invasive cascade and could not be confidently used as a reliable prognostic indicator (22). Sanchez et al revealed a deregulation in the CD44 expression pattern in malignant tumors, but did not identify a correlation between this deregulation and clinicopathological factors (23).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

et al. 2016

View full text Add to dashboard Cite

Abstract.A subpopulation of breast cancer cells with cluster of differentiation (CD)44-positive and CD24-negative expression has been reported to have stem cell properties and to have a higher tumorigenic capacity than other cells. However, the clinico pathological characteristics of this subpopulation are not fully understood. In this study, we aimed to identify the correlations between the expression of CD44 and CD24 and clinicopathological parameters and overall survival. We studied specimens from 262 patients with invasive breast cancer. Immunohistochemical staining for CD44 and CD24 was performed using tissue microarrays. The clinico pathological factors were evaluated from the patients' medical records. In correlation analysis, CD44 expression was significantly associated with human epidermal growth factor receptor 2 (HER2)-negative status (P<0.001). Conversely, CD24 expression was significantly associated with HER2-positive status (P<0.001). CD44 and CD24 expression did not demonstrate any correlation with the age, tumor size, axillary lymph node metastasis status, tumor stage, histological grade, estrogen receptor status and progesterone receptor status of patients. Upon survival analysis, there was no statistical difference in overall survival according to the expression of CD44 and CD24. The results from this study suggest that CD44 and CD24 are clinically significant markers associated with breast tumorigenesis, but not sufficient factors in determining the prognosis of invasive breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The CD44 family includes multiple protein isoforms, encoded by a single gene and generated by alternative splicing, and several of the isoforms have been shown to be overexpressed in malignant cells (94)(95)(96). CD44 is a major cell surface receptor for hyaluronate, and various forms of CD44 could also bind to osteopontin (97,98).…”

Section: Osteopontin Metabolism and Receptorsmentioning

confidence: 99%

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Rodrigues

Teixeira

Schmitt

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

206

144

View full text Add to dashboard Cite

The use of cancer biomarkers to anticipate the outlines of disease has been an emerging issue, especially as cancer treatment has made such positive steps in the last few years. Progress in the development of consistent malignancy markers is imminent because advances in genomics and bioinformatics have allowed the examination of immense amounts of data. Osteopontin is a phosphorylated glycoprotein secreted by activated macrophages, leukocytes, and activated T lymphocytes, and is present in extracellular fluids, at sites of inflammation, and in the extracellular matrix of mineralized tissues. Several physiologic roles have been attributed to osteopontin, i.e., in inflammation and immune function, in mineralized tissues, in vascular tissue, and in kidney. Osteopontin interacts with a variety of cell surface receptors, including several integrins and CD44. Binding of osteopontin to these cell surface receptors stimulates cell adhesion, migration, and specific signaling functions. Overexpression of osteopontin has been found in a variety of cancers, including breast cancer, lung cancer, colorectal cancer, stomach cancer, ovarian cancer, and melanoma. Moreover, osteopontin is present in elevated levels in the blood and plasma of some patients with metastatic cancers. Therefore, suppression of the action of osteopontin may confer significant therapeutic activity, and several strategies for bringing about this suppression have been identified. This review looks at the recent advances in understanding the possible mechanisms by which osteopontin may contribute functionally to malignancy, particularly in breast cancer. Furthermore, the measurement of osteopontin in the blood or tumors of patients with cancer, as a way of providing valuable prognostic information, will be discussed based on emerging clinical data. (Cancer Epidemiol Biomarkers Prev 2007;16(6):1087 -97)

show abstract

“…Clinically relevant animal models of human cancer are important for studies of cancer biology, invasion, and metastasis, and for investigating new methods of prognostic diagnosis and therapy identification. 33,35,36 Experimental models of metastasis of ovarian carcinoma to the lymph node are not available. In the present study, we developed a highly metastatic orthotopic transplantation model of ovarian cancer using SW626-M4, a cell subline of high metastatic potential and low nm23H1 expression, to mimic the natural history of highly metastatic ovarian cancer in humans.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model

Zhou

Chen

et al. 2005

Cancer Gene Ther

View full text Add to dashboard Cite

Ovarian cancer is one of the most threatening malignant tumors in females due to the frequent occurrence of metastasis that precedes diagnosis. The present study explored the possibility of preventing ovarian cancer metastasis by promoting nm23H1 expression through adeno-associated virus (AAV)-mediated gene transfer. A cell line of high metastatic potential, SW626-M4, was derived by in vivo selection and used to establish an ovarian cancer metastasis model in the mouse. Liver metastasis and animal survival time were measured after transfer of a recombinant adeno-associated viral vector expressing nm23H1 (AAV-nm23H1) into the aforementioned model. Intraperitoneal injection of AAV-nm23H1 into this orthotopic implantation model of ovarian cancer resulted in (1) expression of the exogenous gene in more than 95% of tumor cells in situ in nude mice; (2) a 60% reduction in the number of animals developing liver metastases; and (3) a 35-day prolongation of median survival time compared with the untreated host group. In conclusion, the results support the feasibility of induction of nm23H1 expression through gene transfer as a therapeutic strategy for preventing metastases and prolonging host survival time, and indicate that AAV vectors deserve attention in the design of future gene therapy approaches to achieving long-term expression of curative genes in vivo.

show abstract

Adhesion Proteins in the Biology of Breast Cancer: Contribution of CD44

Cited by 93 publications

References 54 publications

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer

The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer

Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model

Contact Info

Product

Resources

About